Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Payables (2021 - 2026)

Atara Biotherapeutics filings provide 6 years of Payables readings, the most recent being $637000.0 for Q1 2026.

  • On a quarterly basis, Payables fell 53.97% to $637000.0 in Q1 2026 year-over-year; TTM through Mar 2026 was $637000.0, a 53.97% decrease, with the full-year FY2025 number at $127000.0, down 97.09% from a year prior.
  • Payables hit $637000.0 in Q1 2026 for Atara Biotherapeutics, up from $127000.0 in the prior quarter.
  • In the past five years, Payables ranged from a high of $12.8 million in Q2 2022 to a low of $127000.0 in Q4 2025.
  • Median Payables over the past 5 years was $4.1 million (2023), compared with a mean of $4.8 million.
  • Biggest five-year swings in Payables: increased 26.95% in 2024 and later crashed 97.09% in 2025.
  • Atara Biotherapeutics' Payables stood at $6.9 million in 2022, then tumbled by 46.38% to $3.7 million in 2023, then rose by 18.54% to $4.4 million in 2024, then crashed by 97.09% to $127000.0 in 2025, then skyrocketed by 401.57% to $637000.0 in 2026.
  • The last three reported values for Payables were $637000.0 (Q1 2026), $127000.0 (Q4 2025), and $318000.0 (Q3 2025) per Business Quant data.